#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16882	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2193	764.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1683	1683	T	954	T	881	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16882	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2193	764.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1417	1417	C	951	C,G	896,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3649	850.8	0	.	n	.	0	T695C	SNP	695	695	T	1090	1090	C	920	C,T	865,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3649	850.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2366	2366	C	1043	C,T,G	965,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3649	850.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2992	2992	T	938	T	892	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31120	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3649	850.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2440	2440	A	1025	A	975	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2474	folP	855	855	100.0	folP.l15.c17.ctg.1	1478	165.8	1	SNP	p	R229S	1	.	.	685	687	AGC	975	977	AGC	233;234;236	A;G;C	217;217;217	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	7024	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3451	202.9	1	SNP	p	S91F	1	.	.	271	273	TTC	581	583	TTC	252;253;257	T;T;C	238;239;242	gyrA.WHO_Z_01155:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	7024	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3451	202.9	1	SNP	p	N95G	0	.	.	283	285	AAC	593	595	AAC	255;256;253	A;A;C	237;237;236	gyrA.WHO_Z_01155:1:1:N95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	7024	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3451	202.9	1	SNP	p	D95N	1	.	.	283	285	AAC	593	595	AAC	255;256;253	A;A;C	237;237;236	gyrA.WHO_Z_01155:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1922	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1216	156.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	415	417	ACC	258;259;255	A;C;C	241;245;241	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1922	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1216	156.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	613	615	CAC	257;255;253	C,T;A;C	240,1;240;239	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1922	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1216	156.4	1	SNP	p	G45D	0	.	.	133	135	GGC	433	435	GGC	247;249;249	G;G;C	229;231;229	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1070	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1035	102.8	0	.	n	.	0	A197.	DEL	197	197	A	573	573	A	253	A	238	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	6632	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3002	220.0	1	SNP	p	S87I	1	S87I	NONSYN	259	261	AGT	565	567	ATT	277;273;274	A;T,G;T	258;253,1;255	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	6632	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3002	220.0	0	.	p	.	0	T518_Q519insR	INS	1552	1552	A	1859	1859	C	279	C	249	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	6632	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3002	220.0	1	SNP	p	D86N	0	.	.	256	258	GAC	562	564	GAC	271;273;275	G;A;C	252;255;260	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	6632	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3002	220.0	1	SNP	p	S88P	0	.	.	262	264	TCC	568	570	TCC	275;282;284	T;C,T;C	256;265,1;265	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5598	parE	1986	1986	99.9	parE.l6.c30.ctg.1	2832	197.1	0	.	p	.	0	T35I	NONSYN	103	105	ACA	475	477	ATA	247;243;242	A;T;A	226;221;223	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5598	parE	1986	1986	99.9	parE.l6.c30.ctg.1	2832	197.1	0	.	p	.	0	D437N	NONSYN	1309	1311	GAT	1681	1683	AAT	280;278;277	A;A,G;T	262;260,1;263	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5598	parE	1986	1986	99.9	parE.l6.c30.ctg.1	2832	197.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1600	1602	GGC	253;254;254	G;G;C	236;238;237	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1311	1313	GCA	297;294;293	G;C;A	265;265;267	penA.18.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1314	1316	ATC	292;289;289	A;T;C	265;266;265	penA.18.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1326	1328	GTG	286;283;283	G;T;G	267;261;264	penA.18.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1326	1328	GTG	286;283;283	G;T;G	267;261;264	penA.18.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1830	1832	ACC	258;255;259	A;C,T;C	237;232,1;237	penA.18.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1884	1886	ACG	256;257;256	A,G;C;G	206,1;211;213	penA.18.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1884	1886	ACG	256;257;256	A,G;C;G	206,1;211;213	penA.18.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2007	2009	AGC	185;186;183	A;G;C	170;168;168	penA.18.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2016	2018	GGC	175;175;174	G;G;C	163;163;160	penA.18.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4762	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2427	195.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2034	2036	CCG	164;166;168	C,G;C;G	131,5;136;136	penA.18.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6752	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3005	223.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1540	1542	CCG	273;274;274	C;C,A;G	238;253,1;247	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2962	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1805	163.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	379	381	GGC	204;203;205	G;G;C	190;188;189	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2962	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1805	163.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	561	561	C	214	C	206	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	R40T	NONSYN	118	120	CGG	451	453	ACA	253;250;250	A;C;A	240;240;239	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	E41K	NONSYN	121	123	GAA	454	456	AAA	251;250;247	A;A;A,G	240;240;236,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	V45S	NONSYN	133	135	GTT	466	468	AGT	245;242;245	A;G;T,A	236;232;234,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	G46K	NONSYN	136	138	GGC	469	471	AAA	248;246;247	A;A;A	237;235;239	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	G48E	NONSYN	142	144	GGA	475	477	GAA	249;249;249	G;A;A	238;238;238	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	S54A	NONSYN	160	162	TCC	493	495	GCC	245;249;249	G,T;C;C,T	226,1;233;233,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	D121G	NONSYN	361	363	GAC	694	696	GGC	260;258;259	G;G,A;C	247;243,1;243	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	Q143K	NONSYN	427	429	CAA	760	762	AAA	273;270;272	A,G;A,G;A	251,1;248,1;249	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	A151V	NONSYN	451	453	GCA	784	786	GTA	273;270;275	G;T,C;A	259;258,1;258	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	Y255W	NONSYN	763	765	TAC	1096	1098	TGG	248;247;250	T;G;G	234;234;237	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	0	.	p	.	0	L277V	NONSYN	829	831	TTA	1162	1164	GTA	264;269;267	G;T;A,T	249;252;253,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	3196	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	1586	200.5	1	SNP	p	G120K	1	.	.	358	360	AAG	691	693	AAG	260;261;259	A;A;G	249;250;249	porB1b.WHO_X_02194c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11998	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	4948	241.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1382	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1023	134.3	1	SNP	p	V57M	1	.	.	169	171	ATG	525	527	ATG	274;275;279	A;T;G	265;266;268	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
